Home > Result Summaries: Compounds > naratriptan > Result Summary for S2WA3001

Result Summary for S2WA3001

Result Summary

Protocol ID:	S2WA3001
Clinical Study ID:	S2WA3001
Official Title:	A randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of four doses of oral naratriptan in the acute treatment of a single migraine attack.
Phase:	Phase 3
Study Indications or Diseases:	Migraine Disorders
Generic Name:	naratriptan
Trade/Product Name:	amerge;naramig
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Abstract: Naratriptan tablets are effective and well-tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel- group trial. Klassen, Arthur, Webster, Chris, Laurenza, Antonio, Austin, Randall, and Asgharnejad, Mahnaz American Academy of Neurology 49th Annual Meeting 4/12/1997 Boston, MA; USA Klassen A, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, parallel-group study. Headache 1997;37:640-645.